21 December 2021 | News
Investment in biologics reflects the company’s global commitment to this fast-growing segment of the pharma industry
image credit- shutterstock
Piramal Pharma Ltd (PPL) has announced an investment of Rs 101.77 crore in Hyderabad-based Yapan Bio, augmenting the capabilities of its Contract Development and Manufacturing Organization (CDMO) business, Piramal Pharma Solutions (PPS).
PPL holds 27.78% equity stake in the company as a result of this investment. As PPS continues to strengthen its capabilities and position itself as a leading CDMO, this acquisition marks a significant addition to PPS’ global capabilities in the development and manufacturing of large molecules for human clinical trials.
Yapan Bio provides process development, scale-up, and cGMP compliant manufacturing of vaccines and biologics/bio-therapeutics, including high containment product classes (up to BSL-2+), recombinant vaccines, RNA/DNA vaccines, gene therapies, monoclonal antibodies, therapeutic proteins, and other complex biologics.
Yapan’s FY21 turnover was Rs 12.4 crore. The company has already earned revenues of Rs 11.8 crore for H1FY22 and is poised for fast growth in response to strong market demand.